Pluri Inc. is an Israeli biotech using placenta-derived cell therapies for degenerative & ischemic conditions.
CEO: Yaky Yanay
CSO: Dr. Arthur Machlenkin
Placental allogeneic cells secrete therapeutic proteins in response to inflammation/ischemia, modulating immune responses and promoting tissue repair.
NCT03006770 (Completed)